Abstract
We evaluated the control of cardiovascular disease (CVD) risk factors among patients with atherosclerotic cardiovascular disease (ASCVD) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in the Arabian Gulf. Of the 4398 enrolled patients, overall mean age was 57 ± 11 years, 60% were males, 13% were smokers, 76% had diabetes, 71% had metabolic syndrome and 78% had very high ASCVD risk status. The proportion of subjects with body mass index <25 kg/m2, HbA1c <7% (in diabetics), low-density lipoprotein cholesterol (LDL-C) <2.6 mmol/L (100 mg/dL) and <1.8 mmol/L (70 mg/dL) for high and very high ASCVD risk cohorts, respectively and controlled blood pressure (<140/90 mmHg) was 14, 26, 31% and 60%, respectively. Only 1.4% of the participants had all of their CVD risk factors controlled with significant differences among the countries (P < .001). CVD risk goal attainment rates were significantly lower in those with very high ASCVD risk compared with those with high ASCVD risk status (P < .001). Females were also, generally, less likely to attain goals when compared with males (P < .001).
Keywords: Cardiovascular diseases, obesity, blood pressure, diabetes mellitus, non-HDL cholesterol, LDL cholesterol, Arabian Gulf.
Current Vascular Pharmacology
Title:Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf
Volume: 14 Issue: 4
Author(s): Mohammed Fakhry, Khalid Al-Rasadi, Khamis Al-Hashmi, Khalid Al-Waili, Raul D. Santos, Haitham Amin, Fahad O.A.S. Baslaib, Omar Al-Hallaq, Obaid Al-Jassim, Afzal H. Yusufali, Abdel R. Medani, Hossam Elghetany, Ibrahim Al-Zakwani, Akram Al-Khadra, Othman Metwally, Khalid Al-Nemer, Faisal Al-Anazi, Shorook Al-Herz, Mahmoud Al-Awadhi, Omer Al-Tamimi, Abdullah Shehab, Ali T. Al-Hinai, Mohamed Arafah and Wael Al-Mahmeed
Affiliation:
Keywords: Cardiovascular diseases, obesity, blood pressure, diabetes mellitus, non-HDL cholesterol, LDL cholesterol, Arabian Gulf.
Abstract: We evaluated the control of cardiovascular disease (CVD) risk factors among patients with atherosclerotic cardiovascular disease (ASCVD) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in the Arabian Gulf. Of the 4398 enrolled patients, overall mean age was 57 ± 11 years, 60% were males, 13% were smokers, 76% had diabetes, 71% had metabolic syndrome and 78% had very high ASCVD risk status. The proportion of subjects with body mass index <25 kg/m2, HbA1c <7% (in diabetics), low-density lipoprotein cholesterol (LDL-C) <2.6 mmol/L (100 mg/dL) and <1.8 mmol/L (70 mg/dL) for high and very high ASCVD risk cohorts, respectively and controlled blood pressure (<140/90 mmHg) was 14, 26, 31% and 60%, respectively. Only 1.4% of the participants had all of their CVD risk factors controlled with significant differences among the countries (P < .001). CVD risk goal attainment rates were significantly lower in those with very high ASCVD risk compared with those with high ASCVD risk status (P < .001). Females were also, generally, less likely to attain goals when compared with males (P < .001).
Export Options
About this article
Cite this article as:
Fakhry Mohammed, Al-Rasadi Khalid, Al-Hashmi Khamis, Al-Waili Khalid, Santos D. Raul, Amin Haitham, Baslaib O.A.S. Fahad, Al-Hallaq Omar, Al-Jassim Obaid, Yusufali H. Afzal, Medani R. Abdel, Elghetany Hossam, Al-Zakwani Ibrahim, Al-Khadra Akram, Metwally Othman, Al-Nemer Khalid, Al-Anazi Faisal, Al-Herz Shorook, Al-Awadhi Mahmoud, Al-Tamimi Omer, Shehab Abdullah, Al-Hinai T. Ali, Arafah Mohamed and Al-Mahmeed Wael, Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf, Current Vascular Pharmacology 2016; 14 (4) . https://dx.doi.org/10.2174/1570161113666151026115921
DOI https://dx.doi.org/10.2174/1570161113666151026115921 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microvascular Function/Dysfunction Downstream a Coronary Stenosis
Current Pharmaceutical Design Effect of Rosuvastatin on Non-alcoholic Steatohepatitis in Patients with Metabolic Syndrome and Hypercholesterolaemia: A Preliminary Report
Current Vascular Pharmacology Role of Cardiac Magnetic Resonance Imaging in Patients with Idiopathic Ventricular Arrhythmias
Current Cardiology Reviews Editorial (Thematic Issue: Frontiers in Atherosclerosis, Heart Disease and Diabetes)
Cardiovascular & Hematological Disorders-Drug Targets Editorial: Exploring Lipid-related Treatment Options for the Treatment of NASH
Current Vascular Pharmacology Evaluation and Comparative Correlation of Abdominal Fat Related Parameters in Obese and Non-obese Groups Using Computed Tomography
Current Medical Imaging Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome
Current Pharmaceutical Design Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Procyanidins and Their Healthy Protective Effects Against Type 2 Diabetes
Current Medicinal Chemistry Atherosclerosis as an Inflammatory Disease
Current Pharmaceutical Design Gene Therapy for Osteoinduction
Current Gene Therapy Thyroid Disorders in Chronic Heart Failure: From Prognostic Set-up to Therapeutic Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Algorithms and Criteria for Transcatheter Aortic Valve Replacement Patient Selection: Current Status and Future Trends
Current Pharmaceutical Design General Aspects of Metal Toxicity
Current Medicinal Chemistry Integrating Pharmacogenetics for Assessment of Herb-Drug Interactions: Has the Time Come?
Current Pharmacogenomics and Personalized Medicine Coenzyme Q10 Reduction with Statins: Another Pleiotropic Effect
Current Drug Therapy MicroRNA-34a Promotes Cardiomyocyte Apoptosis Post Myocardial Infarction Through Down-regulating Aldehyde Dehydrogenase 2
Current Pharmaceutical Design Bioinformatics Analysis of Functional Protein Sequences Reveals a Role for Tumor Necrosis Factor-α and Nitric Oxide in Insulin Resistance Syndrome
Current Nutrition & Food Science Adipose Tissue as a Target of HIV-1 Antiretroviral Drugs. Potential Consequences on Metabolic Regulations
Current Pharmaceutical Design Plasticity of Neuroendocrine-Immune Interactions During Ontogeny: Role of Perinatal Programming in Pathogenesis of Inflammation and Stress- Related Diseases in Adults
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)